Anavex withdraws EU marketing application for blarcamesine for early Alzheimer's after CHMP negative feedback

ANAVEX LIFE SCIENCES CORP.

Withdrew EU marketing authorization application for blarcamesine as add-on therapy for early Alzheimer's disease.
Decision follows CHMP indication it would not issue a positive opinion at this time.
Company will gather additional data and conduct further analyses to address CHMP concerns.
Anavex had submitted application after EMA SME Office encouragement in October 2023.
CEO affirms commitment to advancing oral therapies for early Alzheimer's and continuing regulatory engagement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.